MXPA98009259A - Aspenate of adenosine, its method of preparation from adenosine, and its use for the preparation of medicines for the treatment of fibrosive hepatic diseases and pharmaceut composition - Google Patents
Aspenate of adenosine, its method of preparation from adenosine, and its use for the preparation of medicines for the treatment of fibrosive hepatic diseases and pharmaceut compositionInfo
- Publication number
- MXPA98009259A MXPA98009259A MXPA/A/1998/009259A MX9809259A MXPA98009259A MX PA98009259 A MXPA98009259 A MX PA98009259A MX 9809259 A MX9809259 A MX 9809259A MX PA98009259 A MXPA98009259 A MX PA98009259A
- Authority
- MX
- Mexico
- Prior art keywords
- adenosine
- liver
- aspartate
- formula
- treatment
- Prior art date
Links
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 title claims abstract description 105
- 239000002126 C01EB10 - Adenosine Substances 0.000 title claims abstract description 105
- 229960005305 adenosine Drugs 0.000 title claims abstract description 105
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 title claims abstract description 99
- 201000009673 liver disease Diseases 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims description 9
- 239000000203 mixture Substances 0.000 title claims description 3
- 229940079593 drugs Drugs 0.000 title description 5
- 210000004185 Liver Anatomy 0.000 claims abstract description 56
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229940009098 Aspartate Drugs 0.000 claims abstract description 44
- 201000004044 liver cirrhosis Diseases 0.000 claims abstract description 26
- 230000002440 hepatic Effects 0.000 claims abstract description 23
- 210000001519 tissues Anatomy 0.000 claims abstract description 14
- 230000003176 fibrotic Effects 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 208000006454 Hepatitis Diseases 0.000 claims abstract description 6
- 230000004075 alteration Effects 0.000 claims abstract description 6
- 230000001413 cellular Effects 0.000 claims abstract description 5
- 231100000832 liver cell necrosis Toxicity 0.000 claims abstract description 5
- 238000002054 transplantation Methods 0.000 claims abstract description 4
- 230000004064 dysfunction Effects 0.000 claims abstract description 3
- 231100000241 scar Toxicity 0.000 claims abstract description 3
- 206010008909 Chronic hepatitis Diseases 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- -1 adenosine compound Chemical class 0.000 claims description 9
- 230000003908 liver function Effects 0.000 claims description 9
- 230000008929 regeneration Effects 0.000 claims description 8
- 238000011069 regeneration method Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 238000010606 normalization Methods 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- WIBJXLDWHFLFBG-HJZCUYRDSA-N (3R,4S,5R)-2-(6-amino-7H-purin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N=1C=2N=CNC=2C(N)=NC=1C1O[C@H](CO)[C@@H](O)[C@H]1O WIBJXLDWHFLFBG-HJZCUYRDSA-N 0.000 claims description 3
- 229960005261 Aspartic Acid Drugs 0.000 claims description 3
- 230000036912 Bioavailability Effects 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- 230000035514 bioavailability Effects 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000005755 formation reaction Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000007102 Chronic Brain Damage Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000003612 virological Effects 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 230000001172 regenerating Effects 0.000 abstract description 10
- 239000011780 sodium chloride Substances 0.000 abstract description 8
- 150000003839 salts Chemical class 0.000 abstract description 4
- 230000000840 anti-viral Effects 0.000 abstract description 3
- 230000022534 cell killing Effects 0.000 abstract description 3
- 230000009089 cytolysis Effects 0.000 abstract description 3
- 230000017074 necrotic cell death Effects 0.000 abstract description 3
- 208000008581 Brain Disease Diseases 0.000 abstract description 2
- 206010014623 Encephalopathy Diseases 0.000 abstract description 2
- 206010014625 Encephalopathy Diseases 0.000 abstract description 2
- 208000007232 Portal Hypertension Diseases 0.000 abstract description 2
- 239000000787 lecithin Substances 0.000 abstract description 2
- 235000010445 lecithin Nutrition 0.000 abstract description 2
- 230000000750 progressive Effects 0.000 abstract description 2
- 230000000004 hemodynamic Effects 0.000 abstract 2
- 230000002489 hematologic Effects 0.000 abstract 1
- 230000002443 hepatoprotective Effects 0.000 abstract 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract 1
- 239000011669 selenium Substances 0.000 abstract 1
- 229910052711 selenium Inorganic materials 0.000 abstract 1
- 230000004936 stimulating Effects 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 26
- 230000035492 administration Effects 0.000 description 26
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 22
- 102000008186 Collagen Human genes 0.000 description 21
- 108010035532 Collagen Proteins 0.000 description 21
- 229960005188 collagen Drugs 0.000 description 21
- 229920001436 collagen Polymers 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 230000002194 synthesizing Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000002777 nucleoside Substances 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 210000004027 cells Anatomy 0.000 description 7
- 230000004083 survival Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 6
- 125000003835 nucleoside group Chemical group 0.000 description 6
- 102100001249 ALB Human genes 0.000 description 5
- 101710027066 ALB Proteins 0.000 description 5
- 210000002966 Serum Anatomy 0.000 description 5
- 229940050528 albumin Drugs 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 230000002062 proliferating Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000002441 reversible Effects 0.000 description 5
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine Kinase Proteins 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001684 chronic Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 210000002744 Extracellular Matrix Anatomy 0.000 description 3
- 210000003494 Hepatocytes Anatomy 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001086 cytosolic Effects 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000002496 gastric Effects 0.000 description 3
- 230000002427 irreversible Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002588 toxic Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 102000020504 Collagenase family Human genes 0.000 description 2
- 108060005980 Collagenase family Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 206010019670 Hepatic function abnormal Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 210000004299 High Vocal Center Anatomy 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 210000003470 Mitochondria Anatomy 0.000 description 2
- 206010054107 Nodule Diseases 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003366 colagenolytic Effects 0.000 description 2
- 230000000994 depressed Effects 0.000 description 2
- 230000003352 fibrogenic Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 230000002438 mitochondrial Effects 0.000 description 2
- 230000004065 mitochondrial dysfunctions Effects 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 235000019195 vitamin supplement Nutrition 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N Adenosine monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 108010082126 Alanine Transaminase Proteins 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 206010061008 Biliary tract disease Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 108010075027 Cytochromes a Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102100010966 GPT Human genes 0.000 description 1
- 206010017604 Galactosaemia Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000007345 Glycogen Storage Disease Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 206010019641 Hepatic cirrhosis Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 229940029985 MINERAL SUPPLEMENTS Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- JGSILCHQHQWDPN-ZAUOCLJLSA-N OC(=O)[C@@H](N)CC(O)=O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Chemical compound OC(=O)[C@@H](N)CC(O)=O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JGSILCHQHQWDPN-ZAUOCLJLSA-N 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 206010036181 Porphyria Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 229940081973 S-Adenosylmethionine Drugs 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine zwitterion Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001768 Subcellular Fractions Anatomy 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 201000001203 Wilson disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000035569 catabolism Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 231100000739 chronic poisoning Toxicity 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003057 hepatoprotector Effects 0.000 description 1
- 230000003494 hepatotrophic Effects 0.000 description 1
- 230000000640 hydroxylating Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 200000000011 liver disorder Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 238000005020 pharmaceutical industry Methods 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 235000021087 polyunsaturated fatty acids-rich diet Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Abstract
The present invention relates to: A method for the preparation of adenosine aspartate from adenosine, pharmaceutical composition containing them and uses thereof for the treatment of patients with fibrosing liver diseases, such as cirrhosis and chronic hepatitis, of any type etiology and that are frequently accompanied by hepatic dysfunction, hemodynamic and hematological alterations, as well as signs of progressive encephalopathy. This use involves the administration of adenosine or a more soluble derivative, in the form of the salt of enteral adenosine aspartate, in sufficient quantities and times to reduce cell necrosis, stop fibrogenesis, increase the removal of scar tissue, normalize the Hepatic cellular deoxidizing-reducing state, and thus stimulating the regenerative capacity of the diseased tissue, which is heavily damaged in the fibrotic liver. This invention includes the treatment with adenosine or adenosine aspartate in early stages of hepatopathy that involve evident hepatocellular necrosis and / or alterations of the hemodynamic type, such as portal hypertension. The proposed treatment can be given simultaneously, or alternately, with anti-viral treatments, or with molecules considered hepatoprotective as zinc, selenium or poly-unsaturated lecithins. This method is proposed as a possible alternative to liver transplantation
Description
METHOD FOR PREPARING ADENOSINE ASPARTATE FROM ADENOSINE, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USES OF THEM IN THE TREATMENT OF FIBROSIVE HEPATIC DISEASES
TECHNICAL FIELD OF THE INVENTION The present invention relates to a novel use of adenosine and its derivative adenosine aspartate as hepatotrophic agents for the preparation of medicaments in the treatment of fibrosing liver diseases that can cause liver dysfunction and chronic encephalopathy. Also, the invention provides an alternative route for the treatment of liver cirrhosis by obtaining the active compound and preparing a pharmaceutical composition containing it, which has an important commercial value in the pharmaceutical industry and therapeutic application in the field of medicine. .
INTRODUCTION Hepatic fibrotic diseases that degenerate in cirrhosis are characterized by cellular damage, diffuse fibrosis and regeneration nodules with loss of the lobar and vascular architecture of the hepatic parenchyma. The most common causes of hepatic fibrotic disease are chronic alcohol consumption, viral infections of the hepatitis type (HVB, HVC) and as a consequence of chronic cholestasis or biliary tract disease. Less frequently, these pathologies are due to autoimmune diseases, venous congestive heart disease or to metabolic (genetic) disorders, such as Wilson's disease, glycogenosis, porphyria, galactosemia, etc. Alcohol is the most frequent cause of cirrhosis in the western world, since it accounts for 60% of cases and affects mainly male subjects between 40 and 60 years of age. The second cause of this disease is chronic viral hepatitis, especially the HVC type, which is responsible for more than 90% of cases of post-blood transfusion hepatitis, which evolves in almost 40% to cirrhosis. In Mexico, cirrhosis occupies the second cause of death in the population of productive age (45 to 65 years) and deaths from liver disease of any etiology represent 6% of the national total. Despite the advance in the knowledge of hepatic fibrotic diseases, there is no curative treatment of pharmacological type.
BACKGROUND OF THE INVENTION The present invention refers to the use of the enteral administration of adenosine aspartate, prepared from adenosine to restore the proliferative capacity of the liver tissue, thus stopping the fibrogenesis that occurs in liver disorders that end in cirrhotic symptoms, without import the etiological agent. The cirrhotic liver results from the imbalance of both the existing collagen, as well as that which is synthesized de novo and its degradation. This picture is accompanied by the presence of nodules that sequester liver cells in regeneration, isolating them in extensive areas of fibrosis. These findings indicate that the liver regenerative process is severely altered in an adverse way
(Stocker and ullstein. "Capacity of liver regeneration after partial hepatectomy in cirrhotic ..." Liver Regeneration
After Experimental Injury. New York Stratton, 66-74. 1973). Therefore, it is expected that the regenerative response would be deficient when the fibrosis begins to settle in the liver tissue. When multilobar necrosis occurs, the hepatic regenerative response is triggered by the proliferation of a group of cells that have characteristics similar to biliary cells, which could be dedifferentiated cells (hepatocytes), or may be due to the presence of pluripotent cells, which They are not normally found in the proliferative response that follows the surgical loss of healthy liver tissue (Callea et al., "Cirrhosis of the liver." A regenerative process. -Dig. Dis. Sci., vol 36, 1287-1293. The latter is confirmed by the discovery that liver regeneration is delayed when there is epithelial damage, such as occurs in the cirrhotic liver.; in such a way, there is an inverse correlation between the index of fibrosis in the liver and its regenerative capacity (Macintosh et al., "Hepatic fibrosis as a predictor of hepatic regenerative ..." Hepatology, vol.17, 307-309, 1992) . The physio-pathological mechanism involved in the generation of hepatic fibrotic symptoms is still unknown in its entirety. However, it is known that hepatocellular necrosis plays an important initial role in fibrogenesis, and is demonstrated by the significant increase in the liver "escape enzymes" that occur in cirrhotic patients. This event is gradually accompanied by a deficient hepatic function, which highlights the decrease in the serum availability of albumin (which produces generalized edema), and alterations in coagulation (due to the lack of hepatic synthesis of the coagulation factors) (Van Eyken et al. "A cytokeratin-immunohistochemical study of nodular focal ..." Liver, vol.9, 372-377, 1989). This deficient function of the liver favors the increase in the free pool of the precursor in the synthesis of collagen (proline), increasing the synthesis of this protein as the main element of the extracellular matrix. In fact, the synthesis of de novo collagen is greatly increased in experimental animals that are induced by cirrhosis and this effect is accompanied by a poor removal of collagen tissue already deposited. The latter is due to a decrease in the amount or activity of enzymes responsible for the degradation of collagen (collagenases), and / or changes in the structure of the collagen (amount of aldehydes and glycosaminoglycans), which promotes that said collagen was less susceptible to its enzymatic degradation
(Pérez-Tamayo. "Is cirrhosis of the liver experi entally produced ..." Hepatology, vol 3, 112-120, 1983). The latter would explain why cirrhosis is practically irreversible, despite the removal of the harmful agent that promotes cell necrosis. The role of energy metabolism and intracellular oxide-reduction (redox) reactions in the hepatocyte, as a target of fibrogenic agents, has not been elucidated either. However, it has been suggested that a decrease in the hepatic energy burden in the cirrhotic liver may lead to a lower synthesis of hepatic albumin; however, there is also evidence that the production of albumin by the cirrhotic liver is not altered (Jikko et al., "Adenylate energy charge and cytochrome a in the cirrhotic ..." J. Surg. Res., vol.37, 361-368. 1984). On the other hand, in experimental cirrhosis it has been demonstrated that there are alterations in the redox state, both cytoplasmic and mitochondrial of the hepatocytes. These changes in the redox state promote a metabolic acidosis that leads to the synthesis of the collagen precursor (proline) and the subsequent hydroxylation of said proline in the synthesis of collagen, in such a way promoting its deposition in a liver tissue with a damaged regenerative capacity
(Hernández-Muñoz et al. "Possible role of cell redox state on collagen metabolism ..." Biochim, Biophys, Acta, vol.1002, 93-99, 1994). The effects described above are the result of a progressive mitochondrial dysfunction that accompanies the fibrogenic process. In this context we have found that during the induction of experimental cirrhosis, mitochondria isolated from these livers show a decrease in oxygen consumption, a decrease in respiratory control and a poor use of ADP, the latter being what would promote a poor synthesis of ATP, by the mitochondria of cirrhotic livers (Hernández-Muñoz et al. "Effects of adenosine administration on the function ..." Arch. Biochem. Biophys., vol, 294, 160-167, 1992). In sum, accelerated hepatocellular necrosis, not accompanied by efficient restorative cell proliferation, promotes mitochondrial dysfunction. The changes of the redox state, together with the low mitochondrial synthesis of ATP, promote the availability of substrates for extracellular matrix synthesis. The fact that this accelerated synthesis of collagen is not followed by a remodeling of the hepatic stroma (due to deficient collagenolytic activity), propitiates the healing of large areas of the liver parenchyma, leading to hepatic fibrosis and, even, cirrhosis. experimental, and those found in patients with various liver diseases. Although several therapeutic approaches have been used to try to stop and reverse the fibrotic process, cirrhosis continues to be considered as an irreversible type of picture that gradually progresses to the death of the patient. These therapeutic measures have included diets with low fat content and vitamin supplements; antifibrotic-type medications that have side effects such as diarrhea and gastritis. Anti-inflammatories such as steroids, in order to inhibit the synthesis of collagen, but which produce adverse effects such as hyperglycemia, glaucoma and arterial hypertension. More recently, S-adenosylmethionine has been used as a hepatoprotector, promoting an improvement in the hepatic steatosis (fatty liver). The only method currently chosen for the treatment of cirrhosis is orthotopic liver transplantation, which has shown a survival of 70% a year after surgery. Its obvious disadvantages are the lack of donors and the cost of the procedure. In the model of experimental cirrhosis induced by the chronic administration of carbon tetrachloride to the rat, the administration of adenosine has given beneficial results in the control of this pathology. The administration of adenosine (200 mg / kg of weight) during the induction of experimental cirrhosis, reduces collagen accumulation, notably improving the histological picture of the cirrogenic process. This effect is accompanied by a marked improvement in liver function tests and energy parameters of the liver. The remodeling of the extracellular matrix seems to be due to an increased activity of collagenase. The increase in the availability of cellular energy and the collagenolytic activity of the fibrotic liver, induced by the administration of adenosine, is related to a normalization of the intracellular redox state, due to a protection of mitochondrial function (Hernández-Muñoz et al. " Adenosine partially prevents cirrhosis induced ... "Hepatology, vol 12, 242-248, 1990) and (Hernández-Muñoz et al." Balance between oxidative damage and proliferative potential ... "Hepatology, vol 26, 1100-1110,1997 ). All these changes promote an accelerated hepatic proliferative response, which is strongly depressed in the cirrhotic liver. The results already mentioned have led us to test adenosine and its more soluble derivative, which is adenosine aspartate (50 mg / kg of weight) as a possible reversal of a previously induced cirrhosis in the rat. The results obtained are that the cirrhosis is reversible up to 70% with 20 doses of the proposed compound, accompanying this effect of a complete normalization of the global hepatic function, the mitochondrial function and the stimulation of a regenerative process completely abolished in the liver cirrhotic These latter data give the advantage of considering that the cirrhotic process is potentially reversible, probably also in patients. Aspartate adenosine has a greater bioavailability for the treatment of liver diseases, since it is rapidly metabolizable without compromising liver function, this fact constitutes the main contribution of the present invention, given that current pharmacological treatments have not been reported as potential inducers of the hepatic proliferative process
OBJECTIVES OF THE INVENTION One objective of the present invention relates to the treatment of fibrosing liver diseases, by the use of adenosine and / or adenosine aspartate. Another object of the invention is to provide a method for the preparation of the adenosine aspartate salt by the reaction of adenosine and aspartic acid. A further advantage of the invention is to provide a pharmacological compound such as adenosine aspartate, which is rapidly metabolizable, so that this leads to a better and faster assimilation of said compound for the treatment of fibrosing liver diseases. Also provided in the present invention are pharmaceutical compositions containing adenosine and / or adenosine aspartate in therapeutically effective amounts for the treatment of fibrosing liver diseases. Also, as its therapeutic uses that allow the reduction of hepatocellular necrosis, the arrest of fibrogenesis, the increase of the scar tissue removal, the normalization of the hepatic cellular redox state and the stimulation of the regeneration of a fibrotic liver with deep impaired liver function. It is also proposed that the nucleosides of the present invention can be used as an alternative to liver transplantation or as a preparation for a successful achievement of said surgical procedure. Thus, in the present invention is disclosed the process of preparation of adenosine aspartate from adenosine, pharmaceutical composition containing them and uses thereof in the treatment of fibrosing liver diseases.
BRIEF DESCRIPTION OF THE FIGURES Other objects, features and advantages of the invention will be apparent from the following detailed description, from the preferred embodiments, from the appended claims and from the accompanying figures, wherein: Figure 1, represents the liver incorporation of [1C] adenosine or [14C] adenosine aspartate, after oral administration at the same concentration (50 mg / kg body weight) in normal animals; Figure 2 shows the percentage of survival in animals subjected to toxic fulminant hepatitis, by the administration of carbon tetrachloride (2.5 ml / kg of weight); Figure 3, indicates in cirrhotic animals (30 doses of 0.15 ml / kg of carbon tetrachloride), the increase in the amount of collagen (more than 5 times over the control) and the reversal effect of both adenosine and aspartate of adenosine (4 and 8 weeks); Figure 4 shows the liver function, measured as the serum activity of escape enzymes and the amount of albumin and bilirubin in cirrhotic animals, and the effect of adenosine aspartate; and Figure 5 shows the activity of thymidine kinase in liver samples, as a marker of cell proliferation, in cirrhotic animals treated with adenosine or with adenosine aspartate (4 and 8 weeks).
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to the compound known as adenosine (6-amino-ribofuranosyl purine) having the following formula (I):
ADE OSIUA (I)
Adenosine is a nucleoside widely distributed in nature, and is found in small amounts in almost all mammalian tissues. A second product derived from adenosine (ADO) can be synthesized, giving rise to an adenosine salt with the aspartic amino acid, which corresponds to the aspartate of the ADO (6-amino-ribofuranosyl) whose formula (II) is shown below and the reaction to obtain it is the following:
ASPA RTATO AGENO S IKA
Due to its non-polar condition, both ia 'denosina and su. salt, the ADO aspartate are easily permeable through cell membranes, which allows its enteral administration to be effective. Since there is practically no gastrointestinal catabolism for adenosine and for ADO aspartate, its absorption through the gastro-intestinal system allows it to reach the liver as a target organ, through the portal circulation. Therefore, its administration can be done both in non-enteric capsules and in tablets with a cover of the same nature. In this way, enteral administration of both adenosine and ADO aspartate could be highly effective in patients with impaired liver function to a lesser or greater degree. Based on the foregoing, the preferred way to apply the present invention is through the enteral administration of adenosine or ADO aspartate in a dose of 500 to 1,200 mg / day, for the treatment of liver diseases for a sufficient time to achieve the desired effect. The use of both nucleosides does not exclude the * administration of antivirals, vitamin and mineral supplements, diets rich in polyunsaturated fatty acids (for example: lecithins) or other control drugs for portal hypertension, hyperglycemia or those for palliative treatment of encephalopathy. hepatic origin. The preparation of a pharmaceutical composition that includes a therapeutically effective amount of adenosine and / or adenosine asparrate, can be carried out by employing standard techniques well known to those skilled in the art in combination with pharmaceutically acceptable carriers, such as example, of the degradable type. Adenosine is a natural product with a very active metabolism. However, ADO aspartate does not occur naturally in the metabolism of mammals. Hence, that its preparation represents a method as part of the cited invention.
The method consists in mixing equimolar concentrations of adenosine and aspartic acid dissolved in water under constant agitation, at room temperature and normal pressure. The final pH of the preparation will vary between 6.0 and 7.5. The time required for the formation of the compound is that in which a total solubility of the concentrations of the compounds is achieved separately, and its total lyophilization occurs. The formation of this salt can be easily checked by infrared spectroscopy and determine its melting point. These methods have shown that 'ADO aspartate has a melting point of 216-218 ° C and an infrared spectrum completely different from that of adenosine, whose melting point is 228-230 ° C, and pure aspartic is greater than 311 ° C. The above description and the following examples are intended to illustrate particular modes of carrying out the invention and should not be considered as limiting the scope of protection thereof. EXAMPLES OF THE INVENTION Example 1 The following example demonstrates the bioavailability of both adenosine and ADO aspartate in the liver of normal rats, as well as the protective effect of these molecules on mortality caused by chronic poisoning with carbon tetrachloride at lethal doses.
Male rats of the istar strain with a weight of 180 to 200 g (2 months of age) were used, which were maintained on the basis of a standard diet and with free access to water. The animals were subjected to 12-hour light-dark cycles. On the day of the experiment, a group of normal animals was administered 1 μCi of [14 C] adenosine or [14 C] ADA aspartate, to obtain an estimate of the nucleoside pharmacodynamics. These animals were sacrificed at 15, 30, 60 and
120 min., Taking samples of blood, liver and heart. The samples were deproteinized with 6% perchloric acid, the weight of the sample was quantified and the radioactivity present was counted, as a measure of the presence of adenosine or of adenosine aspartate or its derivatives. To determine the protective effect of the nucleosides, 3 experimental groups were prepared (20 animals per group): group A) received carbon tetrachloride through a gastric tube, in a single dose of 2.5 ml / kg of weight; group B) received carbon tetrachloride and was subsequently administered intraperitoneally 200 mg / kg of adenosine weight; group C) consisted of animals treated with carbon tetrachloride plus 50 mg / kg of aspartyl-ADO. Finally, the control group (n = 5) consisted of rats treated with the vehicle of both drugs (vegetable oil and saline). In the group of animals treated with carbon tetrachloride, the time of death was recorded, calculating the percentage of survival and taking liver samples for histological analysis (light microscopy). Reference is now made to the figures in which a brief explanation of the results obtained is provided, in which figure 1 summarizes the results of the pharmacokinetic distribution of adenosine (Ado) and adenosine aspartate (AspAdo) in the liver of normal rats and follow-up of the 14C mark (μmol) for a time in minutes, T (min) up to 2 hours after the administration of the drug. In the case of the liver concentration of adenosine, it is rapidly concentrated in the liver, after its enteral administration (15 min) and also decays rapidly after that time. Two hours after administration, the adenosine concentration drops to 20% of the initially reached concentration. In the case of animals treated with ADO aspartate, the increase in its concentration in the liver was not as high as in the case of adenosine, but its duration was much longer, suggesting its greater solubility and longer duration in liver tissue. . Figure 2 summarizes the results obtained from the percentage of survival (%) Sv against time in days, T (d), of the administration of adenosine (Ado) and of adenosine aspartate (AspAdo), in the case of fulminant toxic hepatitis (H). The animals that received only the toxic, quickly die in the first 24 hours, which means that after 48 hours the survival in this group is zero. The administration of adenosine in a single dose protects these animals spectacularly, obtaining up to 70% of survival after 3 days of treatment. The administration also in a single dose of ADO aspartate (four times less than adenosine) gave the same effect. Even, the protection obtained with the last compound was slightly higher than that achieved with adenosine.
EXAMPLE 2 The following example demonstrates the reversal effect of experimental cirrhosis, the normalization of liver function and the stimulation of hepatic regeneration in cirrhotic tissue, by the administration of both adenosine and ADO aspartate. Male rats were used, of the Wistar strain with an initial weight of 100 g, subjected to 12-hour cycles of light-dark, and free access to food and water. The animals received an induction treatment of cirrhosis, consisting of the administration of 25μl of carbon tetrachloride diluted in vegetable oil. A total of 30 doses (three times weekly) were administered intraperitoneally. During the induction process, body weight gain was recorded. At the end of the treatment (removal of carbon tetrachloride) the survival was greater than 85% and the animals showed clear histological evidence of cirrhotic alterations in samples taken from livers. Once the population of cirrhotic animals was completed, they were divided into three groups: Group A) cirrhotic rats that received only 10 to 20 doses of saline solution (three administrations per week); group B) cirrhotic rats that received 10 to 20 doses of 10 to 50 mg / kg of adenosine weight (4 and 8 weeks, respectively), and group C) that corresponded to the group of cirrhotic animals that received 20 doses of 50 mg / kg of ADO aspartate (8 weeks). Saline, adenosine and aspartyl-ADO were administered intraperitoneally. As controls, animals of the same age and weight were used, which only received saline intraperitoneally for the same period of time. After three days of the last administration of the aforementioned drugs, the animals underwent a moderate fast and were sacrificed under general anesthesia with sodium pentobarbital. Blood samples were taken from which the serum or plasma was separated, and the entire liver organ was removed and weighed. He also took the spleen and weighed it.
From the whole liver, samples of 1 to 2 grams of tissue were frozen for the determination of the amount of collagen, as a measure of the degree of liver fibrosis. With the rest of the liver, we proceeded to obtain subcellular fractions by differential centrifugation and use of gradients, of which the cytosolic fraction was used for the determination of thymidine kinase activity, as an indicator of the degree of hepatic proliferation. In serum, the levels of albumin and bilirubin were determined by spectrophotometric methods, as well as the activity of glutamic-pyruvic transaminase (TGP) and glutamic-oxaloacetic transaminase (GOT) enzymes. The collagen is extracted from the frozen tissue, as the fraction not soluble in a buffer solution of TRIS-HC1 (pH 7.4). The amount of collagen was determined by its content of hydroxyproline, as an amino acid characteristic of it. Thymidine kinase activity was carried out in the cytosolic fraction by a radiometric method, using thymidine labeled with 14C as substrate. The data are the mean ± standard error of at least 12 animals per group, and the statistical significance of the effects is determined by
Analysis of Variance (ANOVA) and Student's t test. Reference is now made to the figures, in which figure 3 summarizes the results obtained in the amount of hepatic collagen CH in mg / g against the recovery time in weeks TR (S) (degree of fibrosis) in cirrhotic animals (Ci) treated with the vehicle, Control (C) or with the nucleosides. At the end of the treatment with carbon tetrachloride, the amount of collagen increased more than fivefold in the cirrhotic animal and, after treatment with the vehicle, no spontaneous reversion of the picture was found until more than two months of recovery. The animals that received adenosine (Ado) (10 doses in 4 weeks) showed a 35% decrease in the amount of hepatic collagen, and with 20 doses (8 weeks), the amount of collagen decreased up to 63% in the cirrhotic animals. The administration of adenosine aspartate (AspAdo) (20 doses in 8 weeks) promoted a decrease of up to 72% in the degree of fibrosis, evaluated by the amount of collagen; Figure 4 summarizes the effect of nucleosides on the liver function of cirrhotic animals in relation to the number of times over the control (V-Cj versus the recovery time in weeks TR (S).) The cirrhotic animal (Ci) presented high serum levels of TGP and GOT activities and the amount of bilirubin (B), while serum albumin (A) levels were significantly reduced at the end of the induction of cirrhosis. recovery in the cirrhotic animal, with the exception of a gradual increase in the amount of serum albumin.
The administration of both adenosine (Ado) and aspartyl-ADO (10 doses in 4 weeks) completely normalized the altered liver function of the cirrhotic liver, and figure 5 summarizes the effect of the adenosine nucleoside (Ado) and adenosine aspartate (AspAdo) on the regenerative capacity of the cirrhotic liver. At the end of the treatment, the thymidine kinase (TC) activity in relation to the number of times over the control (V-C), as an indicator of DNA synthesis, was found to be increased in the liver of the cirrhotic animal. However, this increase was rapidly depressed during the recovery phase, T-R (S) until not observed 2 months after the cirrogenic induction. The administration of 20 doses of adenosine and ADO aspartate (8 weeks) returned to the liver the ability to regenerate, coupled with the drastic reduction of fibrosis. Therefore, adenosine and its derived salt, ADO aspartate, were able to reverse a cirrhotic picture considered as irreversible, at the same time that normalized liver function and restored the liver capacity of cell proliferation. Likewise, these two nucleosides present an important antiviral activity in the decrease of the viral load in patients affected with viral hepatitis, by means of the analysis of amplification of the viral DNA by PCR of samples obtained from the patients treated with the compounds of this invention, which it is a standard technique well known to those skilled in the art. It is evident that other modifications and variations in accordance with what is set forth in the present invention can be carried out without departing from the spirit and scope thereof, as those skilled in the art will readily appreciate, the invention being protected by the following:
Claims (14)
- CLAIMS 1. A method for the preparation of adenosine aspartate, characterized in that it comprises: reacting the adenosine compound of the formula I with aspartic acid; dissolved in water with constant agitation at room temperature and normal pressure; with a final pH of between about 6.0 to 7.5 during the time required for the formation of the adenosine aspartate of formula II, in which the total solubility of the reactants is achieved, followed by a lyophilization step.
- 2. The method according to claim 1, wherein the adenosine compound of the formula I is 6-amino-ribofuranosyl purine.
- 3. The method according to claim 1, "wherein the adenosine asparate of the formula II, is the 6-amino-ribofuranosyl.
- 4. The adenosine aspartate of formula II, obtained from the method of claim 1, characterized in that it has a melting point of 216 to 218 ° C.
- 5. The adenosine aspartate according to claim 4, characterized in that it also comprises a greater bioavailability and is rapidly metabolizable for the treatment of fibrosing liver diseases such as cirrhosis and chronic hepatitis.
- 6. A pharmaceutical composition comprising a therapeutically effective amount of adenosine and / or adenosine aspartate in combination with a pharmaceutically acceptable carrier of the degradable type for the treatment of fibrosing liver diseases.
- 7. The use of a therapeutically effective amount of the adenosine compound of the formula I and / or of the adenosine aspartate of the formula II, for the preparation of a "medicament for treating fibrotic disorders of the liver, such as cirrhosis leading to dysfunction liver disease of chronic encephalopathy.
- 8. The use according to claim 7, characterized in that the adenosine compound of the formula I is 6-amino-ribofuranosyl purine.
- 9. The use according to claim 7, characterized in that the adenosine asparate of the formula II is 6-amino-ribufuranosyl.
- 10. The use according to claim 7, characterized in that the cirrhosis originates from any congenital, viral or alcohol consumption etiology, associated with secondary secondary pathology.
- 11. The use according to claim 7, characterized in that adenosine and / or adenosine aspartate are administered predominantly enterally.
- The use according to claim 11, characterized in that the adenosine and / or the adenosine aspartate are administered enterally in an effective dose of approximately 10 to 50 mg / kg of weight, with a pharmaceutically acceptable vehicle of the degradable type .
- 13. The use according to claim 7, characterized in that it allows the reduction of hepatocellular necrosis, the arrest of fibrogenesis, the increase in the removal of scar tissue, the normalization of the hepatic cellular status, and the stimulation of the regeneration of a fibrotic liver, with profound alteration of liver function. The use according to claim 7, wherein the adenosine and / or adenosine aspartate is a substitute for liver transplantation or is a preparation for a successful achievement of said surgical procedure.
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA98009259A true MXPA98009259A (en) | 2000-05-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2191677C (en) | Cerebral function improving agents | |
DK167518B1 (en) | PREPARATIONS FOR SYNTHESIS OF PROSTAGLANDINES AND HYDROXYPHETIC ACIDS IN BIOLOGICAL SYSTEMS AND USE OF THESE FOR THE PREPARATION OF MEDICINAL PRODUCTS | |
JP3546227B2 (en) | A method for increasing glutathione levels using glutamine | |
KR20090130187A (en) | Compositions and methods for preventing and treating mucositis and weight loss | |
JP2002542191A (en) | Carnitine and glutathione-containing compositions useful for increasing glutathione absorption and enhancing its effect | |
US20180125805A1 (en) | Prophylactic/therapeutic agent for virus infections which comprises ala compound | |
Maezono et al. | Alanine protects liver from injury caused by D‐galactosamine and CCl4 | |
US20050182135A1 (en) | Enhancement of alcohol metabolism | |
US4996200A (en) | Use of Zn-protoporphyrin for hepatitis treatment | |
US6127342A (en) | Method for preventing or treating a lung disease caused by active oxygen and free radical injury | |
Robinson et al. | Parenteral glutathione monoester enhances tissue antioxidant stores | |
MXPA98009259A (en) | Aspenate of adenosine, its method of preparation from adenosine, and its use for the preparation of medicines for the treatment of fibrosive hepatic diseases and pharmaceut composition | |
EA001099B1 (en) | Injecting medical preparation "citoflavin" possessing cito-pretecting effect | |
Wong et al. | Effects of light on metalloporphyrin‐treated newborn mice | |
RU2096034C1 (en) | Pharmaceutical composition inducing glutathione biosynthesis, glutathione transferase activity and showing antitoxic, radioprotective and antihypoxic action and methods of treatment, prophylaxis and protection using thereof | |
US20130296390A1 (en) | Method and compositions for enhancing the safety of orally administered magnesium alpha-lipoate | |
CA2083609C (en) | Preventive or therapeutic agent for ischemia-reperfusion tissue injury, arrhythmia and lung injury caused by active oxygens and free radicals | |
RU2108095C1 (en) | Medicinal preparation for curing cerebral ischemia | |
US11253495B2 (en) | Pharmaceutical composition for treating excessive lactate production and acidemia | |
KR19990066786A (en) | Liver function improver using Bergenin and its derivatives as active ingredients | |
JPS60208914A (en) | Preventive and remedy for hepatic disorder | |
KOZUKA et al. | Effects of S-adenosyl-L-methionine upon ischemia-induced brain edema in Mongolian gerbils and spontaneously hypertensive rats | |
RU2597785C1 (en) | Hepatoprotective, cardioprotective and placentaprotective, uterolith and no-mimetic combined drug | |
WO2016083399A9 (en) | Alpha-ketoglutarate in combination with glutamate dehydrogenase for treating hyperammonemia | |
Synelnyk | The Institute of Biology and Medicine |